Jonah Feldman

Articles

Iflinatamab Deruxtecan Elicits Clinical Activity in SCLC

September 10th 2023

Treatment with the antibody-drug conjugate ifinatamab deruxtecan in heavily pretreated patients with small cell lung cancer led to promising efficacy and a manageable safety profile.

Fianlimab/Cemiplimab Demonstrates Early Clinical Activity and Safety in Advanced Melanoma

June 6th 2023

The LAG-3 inhibitor fianlimab plus cemiplimab produced high and consistent tumor responses and a comparable toxicity profile to that of anti–PD-L1 monotherapies in patients with advanced melanoma who were PD-L1 inhibitor–naïve in the advanced setting, according to data from a phase 1 study.

BRCA Mutations Associated with Worse Survival in HRR-deficient mCRPC

June 4th 2023

Patients with homologous recombination repair–deficient mutations and metastatic castration-resistant prostate cancer who also harbored BRCA mutations experienced poorer survival outcomes vs patients without BRCA mutations and those with non-BRCA HRR mutations, according to an analysis from the CAPTURE trial.

Eftilagimod Alpha/Pembrolizumab Generates Antitumor Activity in PD-1–Resistant NSCLC

April 3rd 2023

Treatment with eftilagimod alpha plus pembrolizumab resulted in tumor shrinkage and a tolerable safety profile in patients with anti–PD-1/PD-L1–resistant non–small cell lung cancer.

Ruxolitinib Displays Variable Pharmacokinetics in Patients with GVHD 2 Years of Age and Under

February 17th 2023

A study did not find a correlation between the pharmacokinetics and pharmacodynamics of ruxolitinib for the treatment of patients 2 years of age and younger with graft-vs-host disease.

MRD Detection Provides Prognostic Value in Patients With ALL Undergoing HCT

February 16th 2023

The presence of minimal residual disease led to a higher likelihood of relapse in patients with acute lymphoblastic leukemia who underwent hematopoietic cell transplant compared with those who had undetectable MRD pre and post transplant.

Tislelizumab Provides QOL Benefit Over Sorafenib in Unresectable HCC

January 21st 2023

Tislelizumab monotherapy resulted in favorable health-related quality of life outcomes compared with sorafenib as frontline treatment for patients with unresectable hepatocellular carcinoma.

Palbociclib Plus Fulvestrant Fails to Improve PFS in ER+/HER2- Breast Cancer After Progression on a CDK4/6 inhibitor

December 8th 2022

Palbociclib plus fulvestrant did not elicit a progression-free survival benefit vs fulvestrant alone in patients with estrogen receptor–positive/HER2-negative breast cancer who had progressed on prior treatment with a CDK4/6 inhibitor and aromatase inhibitor.

Trastuzumab Deruxtecan at Reduced Dose Maintains Efficacy in HER2-Mutated NSCLC

September 12th 2022

The clinical benefit and tolerable safety profile of trastuzumab deruxtecan was maintained at 5.4 kg/mg vs 6.4 kg/mg in patients with HER2-mutated non–small cell lung cancer, confirming the benefit-risk ratio of the FDA-approved dose.

Isatuximab Plus Carfilzomib/Dexamethasone Maintains Survival Benefit in Relapsed Multiple Myeloma

August 26th 2022

The combination of Isatuximab plus carfilzomib and dexamethasone continued to demonstrate a progression-free survival benefit vs carfilzomib and dexamethasone alone in relapsed multiple myeloma.

Isatuximab-Based Regimens Demonstrate Favorable Safety in Relapsed/Refractory Multiple Myeloma

August 26th 2022

Isatuximab-containing regimens displayed favorable toxicity in patients with relapsed/refractory multiple myeloma in a real-world study.

Larotrectinib Demonstrates Favorable Long-Term Responses in NTRK Fusion–Positive Lung Cancer

August 6th 2022

Larotrectinib continued to elicit durable responses and a low toxicity profile in patients with NTRK fusion–positive lung cancer, according to long-term follow-up data from the phase 2 NAVIGATE trial and phase 1 LOXO-TRK-14001 trial.

Panitumumab Plus Intensified Chemotherapy Fails to Improve Efficacy in mCRC

June 7th 2022

The EGFR inhibitor panitumumab plus a stronger chemotherapy regimen did not demonstrate a significant response benefit over an active chemotherapy comparator plus panitumumab in patients with metastatic colorectal cancer with unmutated RAS and BRAF.

Nivolumab/Ipilimumab Demonstrated Long-term Efficacy in Metastatic NSCLC

June 6th 2022

Results of a 5-year analysis of the phase 3 CheckMate 227 trial showed that the combination of nivolumab plus ipilimumab elicited durable overall survival benefit in patients with metastatic non–small cell lung cancer regardless of PD-L1 expression compared with chemotherapy.

Darolutamide Added to ADT/Docetaxel Shows No Increased Toxicity in mHSPC

May 16th 2022

The combination of darolutamide plus androgen deprivation therapy and docetaxel presents adverse effects that are similar to those experienced with ADT plus docetaxel alone in patients with metastatic hormone-sensitive prostate cancer.

Topical Ruxolitinib Shown to be Effective and Tolerable in Cutaneous cGVHD

April 25th 2022

Topical ruxolitinib has shown improved reduction of body surface area of cutaneous chronic graft-vs-host disease vs standard moisturizer vehicle cream, according to interim study results from a poster presented at the 2022 Transplantation & Cellular Therapy Meetings.

Resistance to CAR T-Cell Therapy Predicted by Epigenetic Biomarkers in Pediatric ALL

April 12th 2022

Resistance to CD19-directed CAR T-cell therapy was associated with molecular characteristics identified in pediatric patients with acute lymphoblastic leukemia.

CAR T-Cell Therapy Demonstrates Efficacy With or Without mRNA Vaccine in Solid Tumors

April 11th 2022

The CAR T-cell therapy BNT211, with or without an mRNA vaccine, produced efficacious and tolerable safety results.

Atezolizumab Fails to Meet PFS End Point in Advanced Penile Squamous Cell Carcinoma

February 20th 2022

Atezolizumab with or without radiotherapy did not demonstrate efficacy in patients with advanced squamous cell carcinoma of the penis.

Leveraging Biomarkers in Endometrial Cancer Requires Careful Integration, More Research

January 27th 2022

Casey M. Cosgrove, MD, discussed the current state of biomarkers in the realm of endometrial cancer and how they may be optimally leveraged for prognostic and predictive purposes.